Peter Sander

Dr. Peter Sander

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in Cell Host & Microbe
Verified
Journal Article
Closed access
SMSharon S. Master
Sharon S. Master
SRSilvana K. Rampini
Silvana K. Rampini
ADAlexander S. Davis
Alexander S. Davis
CKChristine Keller
Christine Keller
SEStefan Ehlers
Stefan Ehlers
VDVojo Deretic
Vojo Deretic

15 May 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
MLMarco Lepore
Marco Lepore
AKArtem Kalinichenko
Artem Kalinichenko
ACAlessia Colone
Alessia Colone
BPBhairav Paleja
Bhairav Paleja
ASAmit Singhal
Amit Singhal
LMLucia Mori
Lucia Mori
Mucosal-associated invariant T (MAIT) cells are abundant in humans and recognize conserved bacterial antigens derived from riboflavin precursors, presented by the non-polymorphic MHC class I-like molecule MR1. Here we show that human MAIT cells are remarkably oligoclonal in both the blood and liver, display high inter-individual homology and exhibit a restricted length CDR3β domain of the TCRVβ chain. We extend this analysis to a second sub-population of MAIT cells expressing a semi-invariant TCR conserved between individuals. Similar to ‘conventional’ MAIT cells, these lymphocytes react to riboflavin-synthesizing microbes in an MR1-restricted manner and infiltrate solid tissues. Both MAIT cell types release Th0, Th1 and Th2 cytokines, and sCD40L in response to bacterial infection, show cytotoxic capacity against infected cells and promote killing of intracellular bacteria, thus suggesting important protective and immunoregulatory functions of these lymphocytes.

12 September 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
SLSakshi Luthra
Sakshi Luthra
ARAnna Rominski
Anna Rominski
PSPeter Sander
Peter Sander
The incidence and prevalence of non-tuberculous mycobacterial (NTM) infections have been increasing worldwide and lately led to an emerging public health problem. Among rapidly growing NTM, Mycobacterium abscessus is the most pathogenic and drug resistant opportunistic germ, responsible for disease manifestations ranging from “curable” skin infections to only “manageable” pulmonary disease. Challenges in M. abscessus treatment stem from the bacteria’s high-level innate resistance and comprise long, costly and non-standardized administration of antimicrobial agents, poor treatment outcomes often related to adverse effects and drug toxicities, and high relapse rates. Drug resistance in M. abscessus is conferred by an assortment of mechanisms. Clinically acquired drug resistance is normally conferred by mutations in the target genes. Intrinsic resistance is attributed to low permeability of M. abscessus cell envelope as well as to (multi)drug export systems. However, expression of numerous enzymes by M. abscessus, which can modify either the drug-target or the drug itself, is the key factor for the pathogen’s phenomenal resistance to most classes of antibiotics used for treatment of other moderate to severe infectious diseases, like macrolides, aminoglycosides, rifamycins, β-lactams and tetracyclines. In 2009, when M. abscessus genome sequence became available, several research groups worldwide started studying M. abscessus antibiotic resistance mechanisms. At first, lack of tools for M. abscessus genetic manipulation severely delayed research endeavors. Nevertheless, the last 5 years, significant progress has been made towards the development of conditional expression and homologous recombination systems for M. abscessus. As a result of recent research efforts, an erythromycin ribosome methyltransferase, two aminoglycoside acetyltransferases, an aminoglycoside phosphotransferase, a rifamycin ADP-ribosyltransferase, a β-lactamase and a monooxygenase were identified to frame the complex and multifaceted intrinsic resistome of M. abscessus, which clearly contributes to complications in treatment of this highly resistant pathogen. Better knowledge of the underlying mechanisms of drug resistance in M. abscessus could improve selection of more effective chemotherapeutic regimen and promote development of novel antimicrobials which can overwhelm the existing resistance mechanisms. This article reviews the currently elucidated molecular mechanisms of antibiotic resistance in M. abscessus, with a focus on its drug-target-modifying and drug-modifying enzymes.

1 May 2002 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
PSPeter Sander
Peter Sander
BSBurkhard Springer
Burkhard Springer
TPTherdsak Prammananan
Therdsak Prammananan
ASAntje Sturmfels
Antje Sturmfels
MKMartin Kappler
Martin Kappler
EBErik C. Böttger
Erik C. Böttger
To study the cost of chromosomal drug resistance mutations to bacteria, we investigated the fitness cost of mutations that confer resistance to different classes of antibiotics affecting bacterial protein synthesis (aminocyclitols, 2-deoxystreptamines, macrolides). We used a model system based on an in vitro competition assay with definedMycobacterium smegmatislaboratory mutants; selected mutations were introduced by genetic techniques to address the possibility that compensatory mutations ameliorate the resistance cost. We found that the chromosomal drug resistance mutations studied often had only a small fitness cost; compensatory mutations were not involved in low-cost or no-cost resistance mutations. When drug resistance mutations found in clinical isolates were considered, selection of those mutations that have little or no fitness cost in the in vitro competition assay seems to occur. These results argue against expectations that link decreased levels of antibiotic consumption with the decline in the level of resistance.

1 October 2001 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
BSBurkhard Springer
Burkhard Springer
YKYishak G. Kidan
Yishak G. Kidan
TPTherdsak Prammananan
Therdsak Prammananan
KEKerstin Ellrott
Kerstin Ellrott
EBErik C. Böttger
Erik C. Böttger
PSPeter Sander
Peter Sander
Chromosomally acquired streptomycin resistance is frequently due to mutations in the gene encoding the ribosomal protein S12, rpsL . The presence of several rRNA operons ( rrn ) and a single rpsL gene in most bacterial genomes prohibits the isolation of streptomycin-resistant mutants in which resistance is mediated by mutations in the 16S rRNA gene ( rrs ). Three strains were constructed in this investigation: Mycobacterium smegmatis rrnB , M. smegmatis rpsL 3+ , and M. smegmatis rrnB rpsL 3+ . M. smegmatis rrnB carries a single functional rrn operon, i.e., rrnA (comprised of 16S, 23S, and 5S rRNA genes) and a single rpsL + gene; M. smegmatis rpsL 3+ is characterized by the presence of two rrn operons ( rrnA and rrnB ) and three rpsL + genes; and M. smegmatis rrnB rpsL 3+ carries a single functional rrn operon ( rrnA ) and three rpsL + genes. By genetically altering the number of rpsL and rrs alleles in the bacterial genome, mutations in rrs conferring streptomycin resistance could be selected, as revealed by analysis of streptomycin-resistant derivatives of M. smegmatis rrnB rpsL 3+ . Besides mutations well known to confer streptomycin resistance, novel streptomycin resistance conferring mutations were isolated. Most of the mutations were found to map to a functional pseudoknot structure within the 530 loop region of the 16S rRNA. One of the mutations observed, i.e., 524G→C, severely distorts the interaction between nucleotides 524G and 507C, a Watson-Crick interaction which has been thought to be essential for ribosome function. The use of the single rRNA allelic M. smegmatis strain should help to elucidate the principles of ribosome-drug interactions.

1 October 2002 in Microbiology
Verified
Journal Article
Closed access
SMS. S. Master
S. S. Master
BSB. Springer
B. Springer
PSPeter Sander
Peter Sander
EBE. C. Boettger
E. C. Boettger
VDV. Deretic
V. Deretic
GTG. S. Timmins
G. S. Timmins
The Mycobacterium tuberculosis ahpC gene, encoding the mycobacterial orthologue of alkylhydroperoxide reductase, undergoes an unusual regulatory cycle. The levels of AhpC alternate between stages of expression silencing in virulent strains grown as aerated cultures, secondary to a natural loss of the regulatory oxyR function in all strains of the tubercle bacillus, and expression activation in static bacilli by a yet undefined mechanism. The reasons for this unorthodox regulatory cycle controlling expression of an antioxidant factor are currently not known. In this work, M. tuberculosis H37Rv and Mycobacterium smegmatis mc2155 ahpC knockout mutants were tested for sensitivity to reactive nitrogen intermediates, in particular peroxynitrite, a highly reactive combinatorial product of reactive nitrogen and oxygen species, and sensitivity to bactericidal mechanisms in resting and activated macrophages. Both M. tuberculosis ahpC::Kmr and M. smegmatis ahpC::Kmr showed increased susceptibility to peroxynitrite. In contrast, inactivation of ahpC in M. tuberculosis did not cause increased sensitivity to donors of NO alone. M. tuberculosis ahpC::Kmr also showed decreased survival in unstimulated macrophages, but the effect was no longer detectable upon IFNγ activation. These studies establish a specific role for ahpC in antioxidant defences involving peroxynitrite and most likely additional cidal mechanisms in macrophages, with the regulatory cycle likely contributing to survival upon coming out of the stationary phase during dormancy (latent infection) or upon transmission to a new host.